Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial.

Margarita Majem Tarruella Jonathan Wade Goldman Thomas JohnChristian GroheKonstantin LaktionovSang-We Kim Terufumi Kato Huu Vinh VuShun LuShanqing LiKye Young Lee Charuwan AkewanlopChong-Jen YuFilippo de MarinisLaura Bonanno Manuel DómineFrances A ShepherdShinji AtagiLingmin ZengDakshayini KulkarniNenad MedicMasahiro TsuboiRoy S HerbstYi-Long Wu

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)

HRQoL was maintained with adjuvant osimertinib in patients with stage IB-IIIA EGFRm NSCLC, who were disease-free after complete resection, with no clinically meaningful differences versus placebo, further supporting adjuvant osimertinib as a new treatment in this setting. See related commentary by Patil and Bunn, p. 2204.

Keyphrases

epidermal growth factor receptor
phase iii
advanced non small cell lung cancer
early stage
open label
tyrosine kinase
small cell lung cancer
clinical trial
phase ii
double blind
placebo controlled
lymph node
randomized controlled trial
type diabetes
metabolic syndrome
prognostic factors